Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 162 publications
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Journal: Research square
Published: July 03, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
Journal: Future oncology (London, England)
Published: April 06, 2026
Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2026
RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2025
Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.
Journal: Cancer cell
Published: July 19, 2025
Improving lung cancer tumor-infiltrating lymphocyte (TIL) manufacturing.
Journal: Cytotherapy
Published: May 24, 2025
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.
Journal: Cancers
Published: April 13, 2025
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.
Journal: Cancer research
Published: April 10, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2024
Last Updated: 09/26/2026